David D. Meek
CIK 1555337 · Chief Executive Officer · last filed 2025-06-24
David D. Meek is a Chief Executive Officer who has filed 38 SEC Form 4 insider transactions across 7 companies since 2012. The most recent filing shows the insider sold $30.5K of QURE on Jun 24, 2025. Across all open-market trades the lifetime net is −$642.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $942.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$942.6K
7
38
-$642.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QURE | Director | 34,190 | $27.57 | $942.6K | -$166.7K | 15 | 2025-06-24 |
| CGEM | Director | — | $13.70 | — | $0 | 2 | 2025-06-16 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 2 | 2024-06-04 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Executive Officer | 151,171 | $58.70 | $8.87M | -$321.3K | 5 | 2023-01-24 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Director | 0 | $2.19 | $0 | $0 | 6 | 2022-07-11 |
| Baxalta Inc (BXLT) Delisted | EVP and President, Oncology | 52,514 | — | — | $0 | 3 | 2016-03-07 |
| ENDOCYTE INC (ECYT) Delisted | Chief Commercial Officer | 7,500 | — | — | -$155.0K | 4 | 2014-02-10 |
Recent Filings
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-24 | QURE | Sell (S) | −2,112 | -$30.5K | EDGAR |
| 2025-06-16 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2025-06-13 | QURE | Grant (A) | +7,970 | $0 | EDGAR |
| 2024-06-21 | QURE | Grant (A) | +8,080 | $0 | EDGAR |
| 2024-06-17 | QURE | Sell (S) | −2,229 | -$11.4K | EDGAR |
| 2024-06-04 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-05-16 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2023-10-16 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | QURE | Mixed | +6,410 | -$43.2K | EDGAR |
| 2023-03-01 | QURE | Sell (S) | −389 | -$7.7K | EDGAR |